These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 32547059)

  • 1. Response to Anti-HER2-Based Treatment in a Patient with Bladder Adenocarcinoma Harboring
    Wang X; Hu W; Xie L
    Onco Targets Ther; 2020; 13():4249-4255. PubMed ID: 32547059
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Response to Trastuzumab and Lapatinib in a Metastatic Colorectal Cancer Harboring HER2 Amplification and HER2 S310F Mutation.
    Wang C; Fakih M
    J Natl Compr Canc Netw; 2021 Jun; 19(6):670-674. PubMed ID: 34214965
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Case Report: Effective Treatment With Pyrotinib and Capecitabine in a Heavily Pretreated Locally Advanced Breast Cancer Harboring Both HER2 Overexpression and Mutant.
    Gao Z; Xu J; Wang Y; Wu J; Sun T
    Front Oncol; 2021; 11():715554. PubMed ID: 34722261
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A
    Wang Z; Li W; Wei Y; An L; Su S; Xi C; Wang K; Hong D; Shi Y
    J Gastrointest Oncol; 2021 Aug; 12(4):1939-1943. PubMed ID: 34532140
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Successful treatment with trastuzumab plus chemotherapy as the first‑line regimen in advanced small bowel adenocarcinoma harboring HER2 amplification: A report of two cases.
    Wang J; Zhu X; Chen J; Liu F; Tang X
    Oncol Lett; 2024 Feb; 27(2):64. PubMed ID: 38192673
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of Pyrotinib in a Heavily Pretreated Patient with Lung Adenocarcinoma Harboring HER2 Amplification and Exon 20 Insertions: A Case Report.
    Shan J; Ruan J; Tan Y; Yan L; Chen S; Du M; Wang L
    Onco Targets Ther; 2020; 13():9849-9856. PubMed ID: 33061462
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Response to Afatinib in a Patient with Non-Small Cell Lung Cancer Harboring HER2 R896G Mutation: A Case Report.
    Lin L; Ge H; Yan Z; Wang G; Wu X; Lv D
    Onco Targets Ther; 2019; 12():10897-10902. PubMed ID: 31849493
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Complete response to trastuzumab and chemotherapy in recurrent urothelial bladder carcinoma with
    Jiang Q; Xie MX; Zhang XC
    World J Clin Cases; 2020 Feb; 8(3):594-599. PubMed ID: 32110671
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Response to Pyrotinib in a Patient with Metastatic Bladder Urothelial Carcinoma Harboring HER2 V842I Mutation: A Case Report.
    Li S; Liu Q; Liu M; Liu T
    Cancer Manag Res; 2022; 14():2927-2932. PubMed ID: 36200096
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical Characteristics and Outcomes of Non-small Cell Lung Cancer Patients with HER2 Alterations in Korea.
    Lee K; Jung HA; Sun JM; Lee SH; Ahn JS; Park K; Ahn MJ
    Cancer Res Treat; 2020 Jan; 52(1):292-300. PubMed ID: 31345011
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of Ado-Trastuzumab Emtansine and Fam-Trastuzumab Deruxtecan on Metastatic Breast Cancer Harboring HER2 Amplification and the L755S Mutation.
    Mukohara T; Hosono A; Mimaki S; Nakayama A; Kusuhara S; Funasaka C; Nakao T; Fukasawa Y; Kondoh C; Harano K; Naito Y; Matsubara N; Tsuchihara K; Kuwata T
    Oncologist; 2021 Aug; 26(8):635-639. PubMed ID: 33559918
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Response to Pyrotinib in a Chinese Patient with Bone-Metastatic Scrotal Paget's Disease Harboring Triple Uncommon HER2 Mutation: A Case Report.
    Guo JJ; Jiao XD; Wu Y; Qin BD; Liu K; Zang YS
    Onco Targets Ther; 2020; 13():6289-6293. PubMed ID: 32753879
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Case report: Long-term clinical benefit of pyrotinib therapy following trastuzumab resistance in
    Fang X; Mou H; Ying X; Hou X; Wang L; Wu Y; Yan N; Guo L; Liao Q
    Front Oncol; 2022; 12():1024677. PubMed ID: 36620566
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Effects of HER2 Alterations in EGFR Mutant Non-small Cell Lung Cancer.
    Nagasaka M; Singh V; Baca Y; Sukari A; Kim C; Mamdani H; Spira AI; Uprety D; Bepler G; Kim ES; Raez LE; Pai SG; Ikpeazu C; Oberley M; Feldman R; Xiu J; Korn WM; Wozniak AJ; Borghaei H; Liu SV
    Clin Lung Cancer; 2022 Jan; 23(1):52-59. PubMed ID: 34801409
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prolonged Response to Trastuzumab in a Patient With HER2-Nonamplified Breast Cancer With Elevated HER2 Dimerization Harboring an ERBB2 S310F Mutation.
    Chumsri S; Weidler J; Ali S; Balasubramanian S; Wallweber G; DeFazio-Eli L; Chenna A; Huang W; DeRidder A; Goicocheal L; Perez EA
    J Natl Compr Canc Netw; 2015 Sep; 13(9):1066-70. PubMed ID: 26358791
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy with Trastuzumab Deruxtecan for Non-Small-Cell Lung Cancer Harboring
    Kato Y; Kato Y; Minegishi Y; Suzuki T; Nakamichi S; Matsumoto M; Miyanaga A; Noro R; Kubota K; Terasaki Y; Seike M; Gemma A
    Onco Targets Ther; 2021; 14():5315-5319. PubMed ID: 34848974
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A Case of HER2 Mutated Colorectal Cancer Treated Successfully With Fam-Trastuzumab Deruxtecan.
    Reddy A; Nwankwo N; Sekar A; Kumar A
    Cureus; 2023 May; 15(5):e38582. PubMed ID: 37284365
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detection of ERBB2 Amplification by Next-Generation Sequencing Predicts HER2 Expression in Colorectal Carcinoma.
    Cenaj O; Ligon AH; Hornick JL; Sholl LM
    Am J Clin Pathol; 2019 Jun; 152(1):97-108. PubMed ID: 31115453
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Re-evaluation of HER2 status in patients with HER2-positive advanced or recurrent gastric cancer refractory to trastuzumab (KSCC1604).
    Saeki H; Oki E; Kashiwada T; Arigami T; Makiyama A; Iwatsuki M; Narita Y; Satake H; Matsuda Y; Sonoda H; Shimokawa M; Maehara Y;
    Eur J Cancer; 2018 Dec; 105():41-49. PubMed ID: 30391779
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A narrative review of advances in treatment and survival prognosis of HER2-positive malignant lung cancers.
    Wu R; Yuan B; Li C; Wang Z; Song Y; Liu H
    J Thorac Dis; 2021 Jun; 13(6):3708-3720. PubMed ID: 34277062
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.